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The discovery of new pharmacologically active substances and drugs modeling led 
to necessity of predicting drugs properties and its ADME data. Angiotensin II receptor 
antagonists are a group of pharmaceuticals  which modulate the renin-angiotensin-
aldosterone system and today represent the most commonly prescribed anti-
hypertensive drugs. The aim of this study was to compare different molecular properties 
of seven angiotensin II receptor antagonists / blockers (ARBs), (eprosartan, irbesartan, 
losartan, olmesartan, telmisartan, valsartan) and their plasma protein binding (PPB) 
data. Several ARBs molecular descriptors were calculated using software package 
Molinspiration Depiction Software as well as Virtual Computational Chemistry Laboratory 
(electronic descriptor – PSA, constitutional parameter – Mw, geometric descriptor – Vol, 
lipophilicity descriptors - logP values, aqueous solubility data – logS). The correlations 
between all collected descriptors and plasma protein binding data obtained from relevant 
literature were established. In the simple linear regression poor correlations were 
obtained in relationships between PPB data and all calculated molecular descriptors.  In 
the next stage of the study multiple linear regression (MLR) was used for correlation of 
PPB data with two different descriptors as independent variables. The best correlation 
(R
2=0.70 with P<0.05) was established between PPB data and molecular weight with 
addition of volume values as independent  variables. The possible application of 
computed molecular descriptors in drugs protein binding evaluation can be of great 
importance in drug research. Acta Medica Medianae 2014;53(1):19-24. 
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Introduction 
 
Fast and reliable evaluation of drug’s 
properties, absorption, distribution, metabolism 
and elimination (ADME) has been recognized as 
critical in accelerating of drug discovery process 
and clinical success of drug candidates (1). 
The number of molecular physicochemical 
properties may significantly influence  drugs 
ADME properties. Lipophilicity, solubility, mole-
cular weight, volume of drug’s molecule, polar 
surface area, play important role in drugs 
absorption, penetration into tissues and degree 
of distribution as well as degree of plasma 
protein binding (PPB) (2-5).  
The drug’s plasma protein binding (PPB) 
degree significantly influences its in vivo effi-
ciency. Drug molecules in vivo are either bound 
to proteins and lipids in plasma (termed plasma 
protein binding (PPB)), to proteins and lipids in 
tissues, or are free (unbound) and diffuse among 
the aqueous environment of the blood and 
tissues. Depending on a specific affinity for 
plasma protein, a portion of the bound and 
unbound drug may differ. In most cases, only 
free drug molecules interact with the therapeutic 
target, a receptor, to produce efficacy. Also, free 
drug’s fraction is the one that can be meta-
bolized and excreted. One of the advantages of 
drug's modeling is the finding of an optimum 
drug's PPB range (6,7).  
Angiotensin II receptor antagonists, also 
known as angiotensin receptor blockers (ARBs), 
AT1-receptor antagonists or sartans, are a group 
of pharmaceuticals which modulate the renin-
angiotensin-aldosterone system. They were intro-
duced in clinical practice three decades ago and 
today represent the most commonly prescribed 
antihypertensive drugs (6,8,9). Their main uses 
are in the treatment of hypertension, diabetic 
nephropathy and congestive heart failure. They 
have been shown to reduce proteinuria in In silico evaluation of angiotensin II receptor antagonist’s plasma...                                                             Jadranka Odović et al. 
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diabetic nephropathy and hospitalization and 
mortality rate in heart failure patients (6,8,9). 
ARBs may be used instead of an angiotensin-
converting enzyme (ACE) inhibitors in patients 
not able to tolerate certain side effects of an ACE 
inhibitor, such as persistent cough. ARBs are well 
tolerated by most individuals. The most common 
side effects are cough, hyperkalemia, hypotension, 
dizziness, headache, drowsiness, diarrhea, abnormal 
taste sensation and rash. Compared to ACE 
inhibitors, cough occurs less often with ARBs. 
Contra-indications for their use are pregnancy 
and bilateral renal artery stenosis (6,8-10). 
Various ARBs are similar in actions and 
side effects. Candesartan Cilexetil, Olmesartan 
Medoxomil and Losartan differ from the other 
compounds in several respects. They are only 
compounds with active metabolites, and they 
have the highest renal elimination (around 35%) 
of all the agents. The ARBs plasma protein 
binding values are relatively similar and range 
from 95 to 100%.  
According to the available literature, a 
number of authors investigated pharmacological 
properties of drugs from ARBs group as well as 
their similarities and differences (11-13). Also, 
the number antihypertensive drug’s acidity, 
lipophilicity, solubility or absorption were theo-
retically considered by the use of computer 
programs based on their molecular structure (3-5). 
In our previous studies, the lipophilicity of 
several ACE inhibitors examined under different 
chromatographic conditions (14-16) was correla-
ted with ACE inhibitors in silico lipophilicity data. 
Also, in recently published papers, ACE inhibitors 
lipophilicity data were correlated in MLR analysis 
(with addition of different molecular descriptors 
as independent variables) with their absorption 
(17) as well as PPB data (18). Continuing these 
researches, the aim of the present study was to 
compare different molecular descriptors of seven  
ARBs (eprosartan, irbesartan, losartan, olmesartan, 
telmisartan, valsartan) and their plasma protein 
binding (PPB) data. 
 
Material and methods 
 
Materials 
 
This study included seven most often 
prescribed ARBs: 1. candesartan, 2. eprosartan, 
3. irbesartan, 4. losartan, 5. olmesartan, 6. tel-
misartan and 7. valsartan (Figure 1). 
 
Methods 
 
The PPB data of examined ARBs were 
obtained from the relevant literature (6). The 
software package Molinspiration Depiction Software 
(Molinspiration Cheminfirmatics) (19) was used 
for the calculation of electronic descriptor-polar 
surface area (PSA); constitutional parameter - 
molecular weight (Mw); geometric descriptor - 
volume value (Vol). Another software package, 
Virtual Computational Chemistry Laboratory (20) 
was used to calculate ARBs lipophilicity descrip-
tors, different logP values (AlogPs, AClogP, AB/logP, 
MilogP, AlogP, MlogP, KOWWIN logP, XLOGP2, 
XLOGP3), as well as their aqueous solubility data 
(logS).  
The Microsoft Excel 2003 and Origin 7.0 
PRO (Origin Lab Corporation, USA) were used to 
perform the statistical analysis of the regression. 
 
Results 
 
In this research seven ARBs - candesartan, 
eprosartan, irbesartan, losartan, olmesartan, telmi-
sartan and valsartan (Figure 1) were studied in 
order to evaluate the  correlation between their 
PPB data collected from relevant literature and 
calculated molecular descriptors.  
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The ARBs molecular descriptors (logP, 
logS, PSA, Vol, Mw) were calculated using the 
software package Molinspiration Depiction Software 
and Virtual Computational Chemistry Laboratory. 
All calculated descriptors, electronic descriptor – 
PSA, constitutional parameter –  Mw, geometric 
descriptor  –  Vol, lipophilicity descriptors  -  logP 
values, as well as aqueous solubility data – logS, 
play important role in drugs PPB and may 
significantly influence ARBs properties.   
The nine different logP values (AlogPs, 
AClogP, AB/logP, MilogP, AlogP, MlogP, KOWWIN 
logP, XLOGP2, XLOGP3) as lipophilicity descrip-
tors of seven investigated ARBs were calculated 
using different software packages (19,20). According 
to Mannhold et al., the methods applied for logP 
calculation can be classified as: substructure-
based and property-based methods (21). Additi-
onally, substructure-based methods can be divided 
into: fragmental and atom-based methods.  
The fragmental methods cut molecules into 
different fragments with application of correction 
factors. The final logP value (KOWWINlogP, 
ClogP, MilogP, etc) is the result of all fragment 
contributions summing. The atom-based method 
cut molecules down to the single atoms and 
commonly does not apply corrections. Several 
logP values (AlogP, XlogP2, XlogP3, etc) can be 
calculated using the atom-based method  (21).  
 
 
 
Figure 2. The relationship between ARBs literature available 
 PPB data (6) and predicted PPBpred data (using molecular  
weight, Mw and volume values, Vol) (R
2 =0.7039) 
The second, property-based methods employ 
the  description of the entire molecules and 
include: methods based on topological descriptors, 
empirical or methods based on molecule’s 3D-
structure (AlogPs) (21).  
The differences between all presented 
calculation methods result in distinctions in 
absolute obtained logP values.  
The PPB data of examined ARBs and their 
calculated molecular descriptors (logS, PSA, Vol, 
Mw) as well as selected logP data calculated 
using different methods are presented in Table 1.  
The relationships between all collected 
descriptors and plasma protein binding data 
obtained from relevant literature were examined. 
The poor correlations obtained using simple 
linear regression indicated the necessity of MLR 
with application of two different descriptors as 
independent variables. The best correlation was 
established between PPB data and molecular 
weight with addition of volume values as inde-
pendent variables. From regression parameters 
obtained in this correlation, predicted PPB data 
were calculated. The correlation between predicted 
and literature available PPB data for ARBs is 
presented in Figure 2. 
 
Discussion 
 
The main topic of this study was to esta-
blish a high throughput approach using simple or 
multiple linear regression (MLR) analysis capable 
for PPB prediction of selected ARBs as well as the 
new synthesized drugs.  
In the first stage of study, the correlations 
between all collected descriptors and plasma 
protein binding data obtained from relevant 
literature were investigated by the use of simple 
linear regression. Since  applied software packages 
(19,20) could calculate nine different lipophilicity 
descriptors, logP values, relationships between all 
calculated logP values and PPB data were 
examined. Very poor correlations (R
2<0.20) were 
obtained in all relationships. For relationship 
between Mw and PPB data, the correlation with 
R
2  value of 0.172 was observed, while for PPB 
data and calculated logP values even lower 
correlations were obtained (R
2<0.10). In addition, 
relationships between PPB data and logS values, 
Vol or PSA provide correlations with R
2<0.03.  
 
Table 1. PPB data and calculated molecular descriptors of investigated ARBs 
 
Compound  1  2  3  4  5  6  7 
PPB %
a
  99.0  98.0  90.0  98.7  99.0  100.0  95.0 
KOWWIN  4.79  6.37  5.31  4.01  3.63  8.42  3.65 
AlogP  4.60  4.78  4.93  4.89  4.18  7.77  4.62 
AlogPs  4.02  3.57  4.51  4.50  3.35  6.66  3.68 
logS  -5.30  -3.60  -5.28  -4.63  -4.68  -5.72  -4.86 
Mw  440.46  424.52  428.54  422.92  446.51  514.63  435.53 
Volume  382.14  380.77  400.20  374.12  403.61  475.76  408.69 
T PSA  118.83  92.42  87.14  92.52  129.82  72.95  112.08 
       
a
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The poor correlations obtained in simple 
linear regression between all five calculated 
descriptor and PPB data indicated the necessity 
for MLR, applying two different descriptors as 
independent variable, probably due to the 
influence of several molecule properties on ARBs 
PPB. 
In the final stage of this study, MLR was 
used for the correlation of PPB data with two 
different descriptors as independent variables. All 
possible correlations were examined. In all exa-
mined relations, established correlation coefficients, 
probability values (P) and F values were consi-
dered. The majority of relationships provide poor 
correlation coefficients (R
2 lower than 0.40) with 
P values much higher than 0.05 and with 
unacceptable F values.  
However, a very good correlation (R
2=0.70 
with P<0.05) was established by MLR between 
PPB data and Mw with addition of Vol as inde-
pendent variables (Figure 2). The values of 
predicted PPB were calculated according to 
presented equations: 
 
PPBpred  (%) = 0.2807 (±0.0927) Mw + 0.2310 
(±0.0862) Vol + 65.5290 (±13.9569)   ...(1) 
 
with n=7,  R
2=0.7039,  S.D.=2.3377,  F=4.7537
   
The correlation presented can be consi-
dered as good, as it was proposed (R
2 from 0.49 
to 0.79) in literature (22), with acceptable P 
values as well as F values.  
In our recently published paper (18) for 
group of angiotensin-converting enzyme (ACE) 
inhibitors, the good correlation (R
2=0.7520) was 
established between protein binding values and 
their KOWWIN logP data. The good correla-tion 
which was found between ARBs plasma protein 
binding values and in silico molecular descriptors 
-  constitutional parameter, Mw and geometric 
descriptor, Vol confirmed that all physicochemical 
molecular properties have significant influence on 
drugs PPB and could play important role in 
clinical success of drugs candidates. Lipinski et al. 
also noted the rise in complexity and size of the 
average drug molecule, resulting in non-
deliverable agents (23). The increased size, high 
log P values or low water solubility led to higher 
protein binding, and higher probability of being 
rapidly cleared metabolically or via biliary 
excretion (24).  
Since high protein binding degree may 
cause decrease of drugs action and activity, the 
application of computed molecular descriptors in 
drugs protein binding prediction can be of great 
importance especially at new synthesized  drugs 
investigations, aiming at  patient’s benefits. The 
calculation of drugs molecular descriptors could 
be considered as high-throughput screening 
technique for evaluation of selected compounds 
protein binding degree - one quarter of respon-
dents (25,8%) believe that people with epilepsy 
see themselves as less valuable compared to 
others, and one-fifth of respondents think that 
patients with epilepsy are stigmatized in our 
community. 
 
Conclusion 
 
The discovery of new pharmacologically 
active substances and drugs modeling led to 
necessity of predicting drugs properties and its 
ADME data. This study included the seven most 
often prescribed ARBs. Five different ARBs 
molecular descriptors were determined using 
software packages. The correlations between 
ARBs  calculated molecular descriptors and their 
plasma protein binding data obtained from 
relevant literature were examined. In simple 
linear regression, very poor correlations were 
obtained in relationships between PPB data and 
all calculated molecular descriptors logP values, 
logS  values, Vol, Mw and PSA indicated the 
necessity for MLR applying two different 
descriptors as independent variable. The best 
correlation was established between PPB data 
and molecular weight with addition of volume 
values as independent variables. The possible 
application of computed molecular descriptors in 
drugs protein binding evaluation can be of great 
importance in drug research. 
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IN SILICO PROCENA VEZIVANJA ZA PROTEINE PLAZME 
ANTAGONISTA RECEPTORA ANGIOTENZINA II PRIMENOM 
IZRAČUNATIH MOLEKULSKIH DESKRIPTORA 
 
Jadranka Odović, Jasna Trbojević-Stanković 
 
 
Ispitivanje novih farmakološki aktivnih supstanci i modeliranje lekova dovelo je do 
neophodnosti predviđanja osobina leka. Cilj istraživanja bio je da se uporede izračunati 
molekulski deskriptori sedam antagonista receptora angiotenzina II (ARBs), (eprosartan, 
irbesartan, losartan, olmesartan, telmisartan, valsartan) sa dostupnim podacima 
njihovog vezivanja za proteine plazme (PPB). Molekulski deskriptori ispitivanih ARBs 
izračunati su korišćenjem softverskih paketa Molinspiration Depiction Software i Virtual 
Computational Chemistry Laboratory. Ispitane su korelacije između  izračunatih 
deskriptora i vrednosti vezivanja za proteine plazme odabranih lekova. Niske vrednosti 
korelacije (R
2<0,20)  dobijene  su  poređenjem  vrednosti  PPB  i  izračunatih  molekulskih 
deskriptora (logP vrednosti, logS vrednosti, vrednosti Vol, molekulske mase Mr i 
vrednosti  polarne  površine  molekula  PSA).  U  sledećoj  fazi  istraživanja,  primenom 
višestruke regresione analize (MLR), ispitana je zavisnost PPB podataka od dva različita 
molekulska deskriptora kao nezavisnih promenljivih. Najbolja korelacija (R
2=0,70 i 
P<0,05) uspostavljena je između PPB podataka i molekulske mase, uz dodatak vrednosti 
Vol kao nezavisnih promenljivih. Mogućnost primene izračunatih molekulskih deskriptora 
u proceni vrednosti vezivanja ispitivanih lekova za proteine plazme od velikog je značaja 
za razvoj i ispitivanje novih lekova. Acta Medica Medianae 2014;53(1):19-24. 
 
Ključne reči: molekulski deskriptori, ARBs, vezivanje za proteine plazme 